Oncology News | pharmaphorum

News

US and UK flags meet on a diagonal, with grey border line

AbbVie joins BMS in taking a hard line on UK drug pricing

AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.

News

Enhertu scores again in early breast cancer

AstraZeneca and Daiichi Sankyo are eyeing regulatory filings for Enhertu in early breast cancer after a second phase 3 trial delivers.

News

Genmab agrees $8bn takeover of cancer biotech Merus

Genmab continues its shift from out-licensing drugs to developing its own drugs with an $8bn deal to buy Merus and its head and neck cancer therapy.

News

Lilly brings second oral SERD to market for breast cancer

Lilly's Inluriyo is the second oral SERD to reach the US market for ESR1-mutated breast cancer, setting up a market tussle with Menarini's Orserdu.

News

BMS eyes filings for myeloma 'celmod' iberdomide

Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

AbbVie joins BMS in taking a hard line on UK drug pricing

Enhertu scores again in early breast cancer

Genmab agrees $8bn takeover of cancer biotech Merus

Lilly brings second oral SERD to market for breast cancer

BMS eyes filings for myeloma 'celmod' iberdomide

Roche's oral SERD comes good in 2nd-line breast cancer trial

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

News

Editor's Picks